1.	Phase II Randomized Study of Doxorubicin with vs without VX-710 (a Multidrug Resistance Inhibitor) for Inoperable Primary Hepatocellular Carcinoma (Summary Last Modified 05/1999) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VX-96-710-003, NCI-V96-0931
2.	Multicenter Phase II Study of VX-710 in Combination with Paclitaxel in Women with Metastatic or Locally Advanced Breast Cancer that is Refractory to Paclitaxel (Summary Last Modified 05/1999) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VX-96-710-004, NCI-V97-1200
3.	VX-710, Doxorubicin, and Vincristine in Treating Patients With Recurrent Small Cell Lung Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDR0000067008, VX-98-710-006, DUMC-1450-98-9, NCI-V99-1537, NCT00003847